All Articles

With real estate worth more than its stock and ambitious R&D plans, Cosmos Health claims it's undervalued. But is an unusual crypto strategy clouding the picture?

Despite massive security investments, known vulnerabilities are wreaking havoc. A new report reveals why AI demands a shift from pre-production to runtime defense.

The Dallas Cowboys are using a new device to build muscle. It’s part of a high-stakes trend where technology is redefining athlete recovery and longevity.

JFrog's inclusion in the Russell 3000 isn't just a corporate win; it's a signal of the market's new respect for the software supply chain's vital role.

As AI and cyber risks escalate, the new 'Chief Trust Officer' role is emerging. HITRUST's appointment of a veteran leader signals a major shift for all.

As a key architect of its global manufacturing retires, Alliance Laundry bets on financial discipline and investor savvy to drive its next growth cycle.

Medscape's new AI symposium aims to guide hematologists through an ethical revolution, promising to enhance, not replace, clinical expertise. Is this the future?

QuadReal's appointment of Deloitte veteran Trevor Nakka signals a strategic pivot, adding elite financial governance to its $98.5B portfolio to fuel a disciplined global expansion.

With an $18M Series A, Novellia is flipping the script on real-world data, empowering patients to solve a decades-old, multi-billion-dollar R&D bottleneck.

The 'better-for-you' brand is betting on a booming peanut butter market with its first non-chocolate snack, a strategic move backed by deep market data.

Co-Diagnostics is developing a point-of-care Ebola test promising 30-minute results. But can it navigate regulatory hurdles and reach the front lines in time?

AI is moving from the cloud to the world around us. New, powerful hardware is making our cities and industries smarter, but it demands a new level of trust.

As AI-powered cyberattacks escalate, one company is fighting fire with fire. Skyhawk Security's award-winning AI Red Team is a game-changer.

Zacks Investment Management launches two new income ETFs, ZINC and PRIZ, targeting an 8% yield. But can their 'simple', research-driven approach deliver?

With a $1.25 billion investment from Apollo Funds, McKesson is spinning off its medical supply unit. Is this a cure for corporate bloat or a new symptom of financialization in healthcare?

As Recursion heads to a key investor conference, it must prove its AI-powered drug discovery platform can deliver financial results, not just scientific promise.

Frazier Healthcare Partners adds Milton Boyer as an EIR, signaling a strategic push into the complex pharmaceutical manufacturing sector with a proven operator.

Ahead of its token launch, nGRND has drawn 855k gamers with a novel promise: rewards backed by preserved, unmined gold. Is this the future of Web3?

A novel probiotic, sourced from an elite athlete's gut, has navigated the FDA's complex regulatory maze, signaling a major shift for the entire industry.

After a turbulent past, Movement is betting its future on a new model for emerging markets, marrying licensed payment rails with blockchain. Is it a true revolution?